Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing

Journal of Clinical Oncology

Volumn 27, Issue 13, 2009, Pages 2111-2113

  Hillner, Bruce E ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BENDAMUSTINE; BEVACIZUMAB; CAPECITABINE; DASATINIB; DOCETAXEL; ERLOTINIB; IXABEPILONE; LENALIDOMIDE; NELARABINE; NILOTINIB; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; FLUOROURACIL;

BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HUMAN; KIDNEY CANCER; METASTASIS; NEOPLASM; PRIORITY JOURNAL; QUALITY OF LIFE; BREAST TUMOR; COST; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MORTALITY; NOTE; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DEOXYCYTIDINE; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 65549153613     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.0534     Document Type: Editorial

References (24)

1. Gavel S: The oncology pipeline: Maturing, competitive, and growing. Oncology Business Review 9:14-16, 2008
2. Reed SD, Li Y, Anstrom KJ, et al: Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracyline and taxane treatment. J Clin Oncol 13:2185-2191, 2009
3. Levine MN, Ganz PA, Haller DG: Economic evaluation in the Journal of Clinical Oncology: Past, present, and future. J Clin Oncol 25:614-616, 2007
4. Chia SK, D'yachkova Y, Kang A, et al: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973-979, 2007
5. Dufresne A, Pivot X, Tournigand C, et al: Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107:275-279, 2008 (Pubitemid 350265698)
6. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Breast Cancer (V 2.2008). http://www.nccn.org/professionals/physician- gls/PDF/breast.pdf
7. National Institute for Health and Clinical Excellence: Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer. Technology Appraisal 62, 2003. http://www.nice.org.uk/nicemedia/pdf/ 62Capecitbreastfullguidance.pdf
8. Tomiak E, Verma S, Trudeau M, et al: Capecitabine in stage IV breast cancer: Practice Guideline Report #1-16 (V 2.2003). http://www.cancercare.on.ca/ pdf/pebc1-16s.pdf
9. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007 (Pubitemid 350232252)
10. Lechleider RJ, Kaminskas E, Jiang X, et al: Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 14:4378-4384, 2008
11. Hortobagyi GN, Perez E, Vrdoljak E, et al: Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials. ASCO Breast Cancer Symposium, September 5-7, 2008, Washington, DC (abstr 186)
12. Horsman J, Furlong W, Feeny D, et al: The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health Qual Life Outcomes 1:54, 2003 (Pubitemid 39111942)
13. Seidman AD: Sequential single-agent chemotherapy for metastatic breast cancer: Therapeutic nihilism or realism? J Clin Oncol 21:577-579, 2003
14. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 21:588-592, 2003 (Pubitemid 46621890)
15. Steinbrook R: Saying no isn't NICE: The travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 359:1977-1981, 2008
16. American College of Physicians: Information on cost-effectiveness: An essential product of a National Comparative Effectiveness Program. Ann Intern Med 148:956-961, 2008
17. Stewart K: The experimental consumer price index for elderly Americans (CPI-E): 1982-2007. Monthly Labor Review 131:19-24, 2008
18. Murray CJ, Evans DB, Acharya A, et al: Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9:235-251, 2000 (Pubitemid 30248640)
19. Sarin R: Criteria for deciding cost-effectiveness for expensive new anticancer agents. J Cancer Res Ther 4:1-2, 2008
20. Central Intelligence Agency: The World Factbook: United States. https://www.cia.gov/library/publications/the-world-factbook/geos/us.html
21. Braithwaite RS, Meltzer DO, King JT, et al: What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule? Med Care 46:349-356, 2008
22. Smith TJ, Cassell JB: Economics of palliative care, in Doyle D, Hanks G, Cherny NI, et al (eds): Oxford Textbook of Palliative Medicine (ed 4). Oxford, United Kingdom, Oxford University Press, 2009
23. McFarlane J, Riggins J, Smith TJ: SPIKE$: A six-step protocol for delivering bad news about the cost of medical care. J Clin Oncol 26:4200-4204, 2008
24. Bristol-Myers Squibb Company: Worldwide Netsales from Continuing Operations by Product. http://media.corporate-ir.net/media-files/irol/10/106664/ product-sales.pdf